nach oben

Erschienen in:

08.02.2018 | Review

First international TNBC conference meeting report

verfasst von: Padmashree Rida, Angela Ogden, Ian O. Ellis, Zsuzsanna Varga, Antonio C. Wolff, Tiffany A. Traina, Christos Hatzis, Julie R. Palmer, Christine B. Ambrosone, Brian D. Lehmann, Rita Nanda, Valerie Montgomery Rice, Otis W. Brawley, Mylin A. Torres, Emad Rakha, Ritu Aneja

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Recently, Georgia State University’s Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. The conference featured a stellar line-up of domestic and international speakers and diverse participants including TNBC survivors, luminaries in breast cancer research, medical students and fellows, clinicians, translational researchers, epidemiologists, biostatisticians, bioinformaticians, and representatives from the industry. This report distills the burning questions that spiked the event and summarizes key themes, findings, unique opportunities and future directions that emerged from this confluence of thought leaders.

Dietze EC, Sistrunk C, Miranda-Carboni G, O’Regan R, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15(4):248–254CrossRefPubMedPubMedCentral

Pareja F, Geyer FC, Marchio C, Burke KA, Weigelt B, Reis-Filho JS (2016) Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2:16036CrossRefPubMedPubMedCentral

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA (2016) Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11(6):e0157368CrossRefPubMedPubMedCentral

Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN et al (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19(19):5533–5540CrossRefPubMed

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767CrossRefPubMedPubMedCentral

Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, Giltnane J, Lacap JA, Crocker L, Young A et al (2017) Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res 23(18):5561–5572CrossRefPubMed

Jiang T, Shi W, Natowicz R, Ononye SN, Wali VB, Kluger Y, Pusztai L, Hatzis C (2014) Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. BMC Genom 15:876CrossRef

Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L et al (2016) Predictors of chemosensitivity in triple negative breast cancer: an integrated genomic analysis. PLOS Med 13(12):e1002193CrossRefPubMedPubMedCentral

Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J (2015) Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol 68(7):506–510CrossRefPubMed

10.

Krishnamurti U, Wetherilt CS, Yang J, Peng L, Li X (2017) Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol 64:7–12CrossRefPubMed

11.

Garcia-Teijido P, Cabal ML, Fernandez IP, Perez YF (2016) Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting. Clin Med Insights Oncol 10(Suppl 1):31–39PubMedPubMedCentral

12.

Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA (2013) Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol 44(10):2055–2063CrossRefPubMedPubMedCentral

13.

Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D et al (2016) Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology 69(1):25–34CrossRefPubMed

14.

Ascierto PA, Daniele B, Hammers H, Hirsh V, Kim J, Licitra L, Nanda R, Pignata S (2017) Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016. J Translational Med 15(1):205CrossRef

15.

Lee S, Cho EY, Park YH, Ahn JS, Im Y-H (2013) Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol 52(1):73–81CrossRefPubMed

16.

Wang J, Chen H, Chen X, Lin H (2016) Expression of tumor-related macrophages and cytokines after surgery of triple-negative breast cancer patients and its implications. Med Sci Monit 22:115–120CrossRefPubMedPubMedCentral

17.

Palmer JR, Castro-Webb N, Bertrand K, Bethea TN, Denis GV (2017) Type II diabetes and incidence of estrogen receptor negative breast cancer in African American women. Cancer Res 77(22):6462–9. https://doi.org/10.1158/0008-5472.CAN-17-1903 CrossRefPubMed

18.

Mahamodhossen YA, Liu W, Rong-Rong Z (2013) Triple-negative breast cancer: new perspectives for novel therapies. Med Oncol (Northwood Lond Engl) 30(3):653CrossRef

19.

Lee A, Djamgoz MBA (2018) Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev 62:110–122CrossRefPubMed

20.

Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J et al (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13(4):890–901CrossRefPubMed

21.

De Michele A, Harding JJ, Telli ML, Munster PN, McKay R, Iliopoulos O, Orford KW, Bennett MK, Mier JW, Owonikoko TK et al (2016) Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). J Clin Oncol 34(15_suppl):1011CrossRef

22.

Strekalova E, Malin D, Good DM, Cryns VL (2015) Methionine deprivation induces a targetable vulnerability in triple-negative breast cancer cells by enhancing TRAIL receptor-2 expression. Clin Cancer Res 21(12):2780–2791CrossRefPubMedPubMedCentral

23.

Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G (2016) New strategies in breast cancer: immunotherapy. Clin Cancer Res 22(9):2105–2110CrossRefPubMed

24.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M et al (2017) Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4537-5 PubMedPubMedCentralCrossRef

25.

Howlader NNA, Krapcho M et al (2015) SEER cancer statistics review, 1975–2012. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015, National Cancer Institute, Bethesda, MD. https://seer.cancer.gov/csr/1975_2012/

26.

Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I et al (2018) Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 68(1):31–54CrossRefPubMed

27.

Hunt BR, Hurlbert MS (2016) Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005–2014. Cancer Epidemiol 45:169–173CrossRefPubMed

28.

Braveman P (2014) What are health disparities and health equity? We need to be clear. Public Health Rep 129(Suppl 2):5–8CrossRefPubMedPubMedCentral

29.

Newman LA, Kaljee LM (2017) Health disparities and triple-negative breast cancer in african american women: a review. JAMA Surg 152(5):485–493CrossRefPubMed

30.

Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, Lund JL, Allott EH, Bethea TN, Hong CC, Cohen SM, Khoury T et al (2017) Biology and etiology of young-onset breast cancers among premenopausal african american women: results from the AMBER Consortium. Cancer Epidemiol Biomark Prev 26(12):1722–1729CrossRef

31.

Ambrosone CB, Young AC, Sucheston LE, Wang D, Yan L, Liu S, Tang L, Hu Q, Freudenheim JL, Shields PG et al (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5(1):237–248CrossRefPubMed

32.

Espinal AC, Buas MF, Wang D, Cheng DT-Y, Sucheston-Campbell L, Hu Q, Yan L, Payne-Ondracek R, Cortes E, Tang L et al (2017) FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Breast Cancer Res Treat 166(2):559–568CrossRefPubMedPubMedCentral

Titel: First international TNBC conference meeting report
verfasst von: Padmashree Rida
Angela Ogden
Ian O. Ellis
Zsuzsanna Varga
Antonio C. Wolff
Tiffany A. Traina
Christos Hatzis
Julie R. Palmer
Christine B. Ambrosone
Brian D. Lehmann
Rita Nanda
Valerie Montgomery Rice
Otis W. Brawley
Mylin A. Torres
Emad Rakha
Ritu Aneja
Publikationsdatum: 08.02.2018
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4692-3

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

First international TNBC conference meeting report

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery

Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?

MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine

Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study

Breast cancer subtype and survival by parity and time since last birth

Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie